SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 185 filers reported holding SAGE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $7,049,000 | -15.6% | 38,500 | -26.7% | 1.38% | -18.4% |
| Q1 2019 | $8,350,000 | +141.1% | 52,500 | +144.2% | 1.70% | +43.1% |
| Q1 2018 | $3,463,000 | +250.5% | 21,500 | +258.3% | 1.19% | +210.5% |
| Q4 2017 | $988,000 | +5.7% | 6,000 | -60.0% | 0.38% | +42.0% |
| Q3 2017 | $935,000 | +67.9% | 15,000 | +114.3% | 0.27% | +37.9% |
| Q2 2017 | $557,000 | -12.8% | 7,000 | -22.2% | 0.20% | -37.7% |
| Q1 2017 | $639,000 | +36.8% | 9,000 | +12.5% | 0.31% | +30.4% |
| Q4 2015 | $467,000 | -80.6% | 8,000 | -75.8% | 0.24% | -77.9% |
| Q2 2015 | $2,409,000 | – | 33,000 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |